Across TCGA pan-cancer cohorts, POM121L10P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated POM121L10P data layer compared with 11 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher POM121L10P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POM121L10P expression acts as an unfavorable survival marker.
LIHC are the cancer types where POM121L10P Mutation most reproducibly stratifies survival.